New Drug Enforcement Administration Guideline for Communicating Controlled Substance Prescriptions to Pharmacies

2011 ◽  
Vol 25 (1) ◽  
pp. 83-89 ◽  
Author(s):  
Drug Enforcement Administration U.S
Keyword(s):  
Drug Enforcement ◽  
Drug Enforcement Administration ◽  
New Drug ◽  
Controlled Substance

ECSTACY: A Review of MDMA and MDA

1987 ◽  
Vol 16 (4) ◽  
pp. 359-372 ◽  
Author(s):  
Robert P. Climko ◽  
Herbert Roehrich ◽  
Donald R. Sweeney ◽  
Jamil Al-Razi
Keyword(s):  
Designer Drugs ◽  
Drug Enforcement ◽  
Methyl Group ◽  
Drug Enforcement Administration ◽  
Controlled Substance

The Drug Enforcement Administration classified the drug methylenedioxymeth-amphetamine, MDMA, also known as Ecstacy, as a Schedule I controlled substance on July 1, 1985. The controversy surrounding the classification of MDMA is related to the question of its efficacy as an adjunct to psychotherapy and the larger issue of how to regulate the production and use of designer drugs. The authors review the literature on MDMA and its predecessor, MDA, a substance that differs from MDMA by one methyl group.

The Impact of Controlled Substance Federal Regulation on the Practice of Pharmacy

1995 ◽  
Vol 8 (3) ◽  
pp. 130-137 ◽  
Author(s):  
Frederick H. Branding
Keyword(s):  
Medical Practice ◽  
Criminal Prosecution ◽  
Federal Regulation ◽  
Drug Enforcement ◽  
Controlled Substances ◽  
Drug Enforcement Administration ◽  
Controlled Substance ◽  
The Impact

The federal Controlled Substances Act requires all registrants, including pharmacists, to keep complete, accurate, and detailed records of the acquisition and disposition of all controlled substances. These records are to be maintained in a readily retrievable manner in order that they may be inspected, verified, and copied by inspectors of the Drug Enforcement Administration. When dispensing controlled substances, pharmacists have a statutorily imposed corresponding responsibility to verify that all prescriptions for controlled substances have been issued by a prescriber in the usual course of that prescriber's legitimate medical practice. Violations of the Controlled Substances Act and regulations can subject pharmacists to a variety of sanctions, ranging from an administrative letter of admoni tion to a civil fine, forfeiture, or criminal prosecution. Copyright © 1991 by W.B. Saunders Company

The Impact of Controlled Substance Federal Regulation on the Practice of Pharmacy

1991 ◽  
Vol 4 (6) ◽  
pp. 372-379
Author(s):  
Frederick H. Branding
Keyword(s):  
Medical Practice ◽  
Criminal Prosecution ◽  
Federal Regulation ◽  
Drug Enforcement ◽  
Controlled Substances ◽  
Drug Enforcement Administration ◽  
Controlled Substance ◽  
The Impact

The federal Controlled Substances Act requires all registrants, including pharmacists, to keep complete, accurate, and detailed records of the acquisition and disposition of all controlled substances. These records are to be maintained in a readily retrievable manner in order that they may be inspected, verified, and copied by inspectors of the Drug Enforcement Administration. When dispensing controlled substances, pharmacists have a statutorily imposed corresponding responsibility to verify that all prescriptions for controlled substances have been issued by a prescriber in the usual course of that prescriber's legitimate medical practice. Violations of the Controlled Substances Act and regulations can subject pharmacists to a variety of sanctions, ranging from an administrative letter of admonition to a civil fine, forfeiture, or criminal prosecution.

scholarly journals Assessment of Controlled Substance Distribution to U.S. Veterinary Teaching Institutions from 2006 to 2019

2020 ◽  
Author(s):  
Brian Piper ◽  
Kenneth McCall ◽  
Lori Kogan ◽  
Peter Hellyer
Keyword(s):  
United States ◽  
Longitudinal Study ◽  
Clinical Relevance ◽  
Teaching Practice ◽  
The United States ◽  
Educational Institutions ◽  
Drug Enforcement ◽  
Drug Enforcement Administration ◽  
Controlled Substance ◽  
Over Time

Objective: To evaluate the changing pattern of distribution of Schedule II and III opioids, barbiturates, and stimulants to veterinary educational institutions in the United States. Design: Longitudinal study. Sample: Veterinary teaching institutions that use Schedule II and III drugs. Procedures: Distribution of controlled substances to veterinary teaching institutions was obtained from the Drug Enforcement Administration’s Automated Reports and Consolidated Orders System (ARCOS) for opioids (e.g. methadone, fentanyl, codeine), barbiturates (pentobarbital, butalbital), and stimulants (amphetamine, methylphenidate, lisdexamfetamine) from 2006 - 2019. Opioids were converted to their morphine milligram equivalents (MME) for evaluation over time. Results: Controlled substance distribution to veterinary schools exhibited dynamic, and agent specific, changes. The total MME for eleven opioids peaked in 2013 and decreased by 17.3% in 2019. Methadone accounted for two-fifths (42.3%) and fentanyl over one-third (35.4%) of the total MME in 2019. Pentobarbital distribution was greatest by weight of all substances studied and peaked in 2011 at 69.4 kg. Stimulants underwent a pronounced decline and were very modest by 2014. Conclusions and Clinical Relevance: Opioids by total MME in veterinary teaching practice have undergone more modest changes than opioids used with humans. Hydrocodone, codeine and recently fentanyl use have declined while methadone increased. Stimulant distribution decreased to become negligible. Together, this pattern of findings warrant continued monitoring.

Detection of 30 Fentanyl Analogs by Commercial Immunoassay Kits

2021 ◽  
Author(s):  
Rebekah E Wharton ◽  
Jerry Casbohm ◽  
Ryan Hoffmaster ◽  
Bobby N Brewer ◽  
M G Finn ◽  
...  
Keyword(s):  
Alkyl Chain ◽  
Cross Reactivity ◽  
Overdose Prevention ◽  
Drug Enforcement ◽  
Drug Enforcement Administration ◽  
Preliminary Information ◽  
Care Workers ◽  
Powder Samples ◽  
Fentanyl Analogs ◽  
Lateral Flow Assays

Abstract Health-care workers, laboratorians and overdose prevention centers rely on commercial immunoassays to detect the presence of fentanyl; however, the cross-reactivity of fentanyl analogs with these kits is largely unknown. To address this, we conducted a pilot study evaluating the detection of 30 fentanyl analogs and metabolites by 19 commercially available kits (9 lateral flow assays, 7 heterogeneous immunoassays and 3 homogenous immunoassays). The analogs selected for analysis were compiled from the Drug Enforcement Administration and National Forensic Laboratory Information System reports from 2015 to 2018. In general, the immunoassays tested were able to detect their intended fentanyl analog and some closely related analogs, but more structurally diverse analogs, including 4-methoxy-butyryl fentanyl and 3-methylfentanyl, were not well detected. Carfentanil was only detected by kits specifically designed for its recognition. In general, analogs with group additions to the piperidine, or bulky rings or long alkyl chain modifications in the N-aryl or alkyl amide regions, were poorly detected compared to other types of modifications. This preliminary information is useful for screening diagnostic, forensic and unknown powder samples for the presence of fentanyl analogs and guiding future testing improvements.

Sign in / Sign up

Export Citation Format

Share Document